Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
10 - Managing Seizure Risk and Stuttering
Published online by Cambridge University Press: 19 October 2021
Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
Summary
While weight gain and other adverse effects can be challenging to treat, seizure management is extremely successful to the extent that recent reviews comment that it should never be a reason to discontinue clozapine treatment. Evidence suggests that psychiatric providers may have adopted this position, as case data on 316 new clozapine starts from 2007 to 2011 at the South London and Maudsley National Health Service Foundation Trust did not list seizures among reasons for clozapine cessation, although 20 other types of adverse drug reactions were cited. Seizures are not unique to clozapine, and antipsychotic package insert warnings in the United States consider this a class effect, although the mechanisms for this common property remain unknown. Recent reviews note rates ranging from 0.2% to 0.5% with other antipsychotics, and a 9% incidence with high-dose chlorpromazine (≥ 1000 mg/day)
- Type
- Chapter
- Information
- The Clozapine HandbookStahl's Handbooks, pp. 190 - 203Publisher: Cambridge University PressPrint publication year: 2019
References
Nielsen, J., Correll, C. U., Manu, P., et al. (2013). Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? Journal of Clinical Psychiatry, 74, 603–613.Google Scholar
Legge, S. E., Hamshere, M., Hayes, R. D., et al. (2016). Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. Schizophrenia Research, 174, 113–119.CrossRefGoogle ScholarPubMed
Williams, A. M. and Park, S. H. (2015). Seizure associated with clozapine: Incidence, etiology, and management. CNS Drugs, 29, 101–111.Google Scholar
Devinsky, O., Honigfeld, G. and Patin, J. (1991). Clozapine-related seizures. Neurology, 41, 369–371.Google Scholar
Pacia, S. V. and Devinsky, O. (1994). Clozapine-related seizures: Experience with 5,629 patients. Neurology, 44, 2247–2249.CrossRefGoogle Scholar
Remington, G., Agid, O., Foussias, G., et al. (2013). Clozapine and therapeutic drug monitoring: Is there sufficient evidence for an upper threshold? Psychopharmacology (Berlin), 225, 505–518.Google Scholar
Wong, J. and Delva, N. (2007). Clozapine-induced seizures: Recognition and treatment. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie, 52, 457–463.Google Scholar
Spatz, R., Lorenzi, E., Kugler, J., et al. (1978). [The incidence of abnormal EEG patterns with clozapine therapy (Author’s transl)]. Arzneimittel-Forschung, 28, 1499–1500.Google Scholar
Gunther, W., Baghai, T., Naber, D., et al. (1993). EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients. Pharmacopsychiatry, 26, 69–74.CrossRefGoogle ScholarPubMed
Varma, S., Bishara, D., Besag, F. M., et al. (2011). Clozapine-related EEG changes and seizures: Dose and plasma-level relationships. Therapeutic Advances in Psychopharmacology, 1, 47–66.CrossRefGoogle ScholarPubMed
Malik, S., Lally, J., Ajnakina, O., et al. (2018). Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research, 195, 267–273.Google Scholar
Jette Pomerleau, V., Dubeau, F. and Ducharme, S. (2017). Clozapine safety and efficacy for interictal psychotic disorder in pharmacoresistant epilepsy. Cognitive and Behaviorla Neurology, 30, 73–76.Google Scholar
Diaz, F. J., Santoro, V., Spina, E., et al. (2008). Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry, 41, 81–91.CrossRefGoogle Scholar
Ronaldson, K. J., Fitzgerald, P. B., Taylor, A. J., et al. (2012). Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study. Schizophrenia Research, 141, 173–178.CrossRefGoogle ScholarPubMed
Ifteni, P., Nielsen, J., Burtea, V., et al. (2014). Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatrica Scandinavica, 130, 25–29.Google Scholar
Murphy, R., Gallagher, A., Sharma, K., et al. (2015). Clozapine-induced stuttering: An estimate of prevalence in the west of Ireland. Therapeutic Advances in Psychopharmacology, 5, 232–236.CrossRefGoogle ScholarPubMed
Peacock, L. and Gerlach, J. (1994). Clozapine treatment in Denmark: Concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. Journal of Clinical Psychiatry, 55, 44–49.Google Scholar
Bak, T. H., Bauer, M., Schaub, R. T., et al. (1995). Myoclonus in patients treated with clozapine: A case series. Journal of Clinical Psychiatry, 56, 418–422.Google ScholarPubMed
Chen, B., Choi, H., Hirsch, L. J., et al. (2017). Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior, 76, 24–31.CrossRefGoogle ScholarPubMed
Bromley, R., Weston, J., Adab, N., et al. (2014). Treatment for epilepsy in pregnancy: Neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews, 10, Cd010236.Google Scholar
Grover, S., Hazari, N. and Kate, N. (2015). Combined use of clozapine and ECT: A review. Acta Neuropsychiatrica, 27, 131–142.Google Scholar